Launch Date
01/26/2024 at 12:30 pm PST
Credit Amount
1.5
Credit Expires
01/26/2024
Recently, interleukin (IL)-23 and the inflammatory IL-23/T-helper (Th)-17 axis have been identified as central drivers of inflammation related to inflammatory bowel disease (IBD). Science in the field of cytokine-targeting therapies, specifically in the field of IL-23 P19 targeting agents, is evolving rapidly, with the first approval in the class occurring in 2022 and several other agents in late-stage development. While all agents within the anti-IL-23 class will have the ability to bind to and neutralize IL-23 via binding to the P19 domain as an essential function, structural differences in the monoclonal antibody Fc fragment result in each agent having an overall unique clinical profile.
This CME Outfitters symposium at the Crohn’s & Colitis Congress (CCC) 2024, entitled Clean-Up on IL-23: Integrating the Science of Inflammatory Targets into Treatment Decision-making in IBD, will feature an expert panel discussion on the science behind cytokine-targeting therapies and will utilize animated 3-D models to discuss therapeutic mechanisms of action (MOAs) of emerging agents, clinical distinctions between therapies, and individualizing treatments for lasting outcomes for patients with IBD.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Gastroenterologists, gastroenterology fellows, physician associates (PAs), nurse practitioners (NPs), nurses and pharmacists
In support of improving patient care, CME Outfitters, LLC, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.50 Interprofessional Continuing Education Credit for learning and change.
CME Outfitters, LLC, designates this Live Activity for a maximum of 1.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is designated for 1.50 contact hours.
This application-based activity is approved for 1.50 contact hours ( 0.15 CEUs) of continuing pharmacy credit ( JA0007185-0000-24-001-L01-P ).
CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.50 AAPA Category 1 CME credits. Approval is valid until 01/26/2025. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 medical knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Dr. Abreu reports the following financial relationships:
Advisory Board and Consultant: AbbVie Inc.; Bristol Myers Squibb Company; Celsius Therapeutics; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; Microba; Pfizer Inc.; and Prometheus Biosciences, Inc.
Dr. Allegretti reports the following financial relationships:
Consultant: AbbVie Inc.; Adiso Therapeutics; Bristol Myers Squibb Company; Ferring Pharmaceuticals; Finch Therapeutics; GSK; Iterative Scopes; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc..; Pfizer Inc.; Roivant Sciences; and Seres Therapeutics
Research Support: Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc.
Speakers Bureau: Abbvie Inc.; Bristol Myers Squibb Company; and Janssen Pharmaceuticals, Inc.
Dr. Rubin reports the following financial relationships:
Consultant: AbbVie Inc. ; Alimentiv Inc.; AltruBio; Amgen Inc.; Avalo Therapeutics, Inc.; Bristol Myers Squibb Company; BUHLMANN Diagnostics Corporation; ClostraBio; Connect BioPharma; Datos Health; EcoR1 Capital; Evinature;; Ferring Pharmaceuticals; Image Analysis Group (IAG); Iterative Health; Janssen Pharmaceuticals, Inc.; Lilly; Menten AI; Odyssey Therapeutics; Pfizer Inc.; Prometheus Biosciences; Reistone Biopharma; NeuroLogica Corp.; Sangamo Therapeutics; Shanghai Pharmaceuticals; Biotherapeutics, Inc.; Takeda Pharmaceuticals U.S.A., Inc.; Target RWE; Tissium; and Trellus Health Inc.
Grants: Takeda Pharmaceuticals U.S.A., Inc.
Stock Shareholder (ownership interest): Iterative Health (options available, none purchased); Datos Health (nonstatutory stock options); and AltruBio (options available, none purchased)
The following individuals have no financial relationships to disclose:
Diane M. Bruessow, MPAS, PA-C, DFAAPA (Peer Reviewer)
Jeffrey Helfand, DO (Peer Reviewer)
Karla E. Crews, MSN, RN (Peer Reviewer)
Mary Gleason, PhD (Planning Committee)
Kasey Brandt, PharmD (Planning Committee)
Susan H. Yarbrough, CHCP (Planning Committee)
Sandra Caballero, PharmD (Planning Committee)
Sharon Tordoff (Planning Committee)
Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.
Call us at 877.CME.PROS (877.263.7767).
MM-135-012624-69